ArticleAnnals of hematology2025

Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma.

Midori Ogasawara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.